Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy - PubMed

Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy

Lena von Bahr et al. Biol Blood Marrow Transplant. 2012 Apr.

Free article

Abstract

Thirty-one patients treated with mesenchymal stromal cells (MSCs) for acute graft-versus-host disease (aGVHD) or hemorrhagic cystitis between 2002 and 2007 were followed to investigate predictors of outcome, immunologic effects in vivo, and long-term survival. There was no correlation between in vitro suppression by MSCs in mixed lymphocyte cultures and outcome. Soluble IL-2 receptors were measured in blood before and after MSC infusion and declined significantly during the first week after MSC infusion (P = .03). Levels of interleukin-6 and HLA-G were unaffected. Infectious complications occurred several years after recovery from aGVHD. Cytomegalovirus viral load was high, and cytomegalovirus disease was common. Among patients recovering from aGVHD, 54% died of late infections, between 4 months and 2 years after MSC treatment. No increase in leukemia relapse or graft rejection was found. Children had a better survival rate than adults (P = .005). In GVHD patients, 1-year survival was 75% in patients who received early-passage MSCs (from passages 1-2) in contrast to 21% using later passage MSCs (from passages 3-4) (P < .01). We conclude that treatment with early-passage MSCs improved survival in patients with therapy-resistant GVHD. Death from infection was common in MSC-treated patients, but there was no increase in leukemia relapse.

Similar articles

• Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.

  Zhao K, Lou R, Huang F, Peng Y, Jiang Z, Huang K, Wu X, Zhang Y, Fan Z, Zhou H, Liu C, Xiao Y, Sun J, Li Y, Xiang P, Liu Q. Zhao K, et al. Biol Blood Marrow Transplant. 2015 Jan;21(1):97-104. doi: 10.1016/j.bbmt.2014.09.030. Epub 2014 Oct 6. Biol Blood Marrow Transplant. 2015. PMID: 25300866 Clinical Trial.

• Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.

  Baron F, Lechanteur C, Willems E, Bruck F, Baudoux E, Seidel L, Vanbellinghen JF, Hafraoui K, Lejeune M, Gothot A, Fillet G, Beguin Y. Baron F, et al. Biol Blood Marrow Transplant. 2010 Jun;16(6):838-47. doi: 10.1016/j.bbmt.2010.01.011. Epub 2010 Jan 28. Biol Blood Marrow Transplant. 2010. PMID: 20109568 Clinical Trial.

• Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study.

  Liu K, Chen Y, Zeng Y, Xu L, Liu D, Chen H, Zhang X, Han W, Wang Y, Zhao T, Wang J, Wang J, Han Q, Zhao C, Huang X. Liu K, et al. Stem Cells Dev. 2011 Oct;20(10):1679-85. doi: 10.1089/scd.2010.0447. Epub 2011 Feb 5. Stem Cells Dev. 2011. PMID: 21142788 Clinical Trial.

• Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages.

  Ringden O, Le Blanc K. Ringden O, et al. Best Pract Res Clin Haematol. 2011 Mar;24(1):65-72. doi: 10.1016/j.beha.2011.01.003. Epub 2011 Feb 25. Best Pract Res Clin Haematol. 2011. PMID: 21396594 Review.

Cited by

• Freshly thawed and continuously cultured human bone marrow-derived mesenchymal stromal cells comparably ameliorate allergic airways inflammation in immunocompetent mice.

  Cruz FF, Borg ZD, Goodwin M, Sokocevic D, Wagner D, McKenna DH, Rocco PR, Weiss DJ. Cruz FF, et al. Stem Cells Transl Med. 2015 Jun;4(6):615-24. doi: 10.5966/sctm.2014-0268. Epub 2015 Apr 29. Stem Cells Transl Med. 2015. PMID: 25925837 Free PMC article.

• Mesenchymal stem cells preconditioned with a TLR5 agonist enhanced immunoregulatory effect through M2 macrophage polarization in a murine graft-versus-host disease model.

  Gil S, Im KI, Kim N, Lee J, Na H, Min GJ, Cho SG. Gil S, et al. Int J Med Sci. 2024 Jun 17;21(9):1649-1660. doi: 10.7150/ijms.93121. eCollection 2024. Int J Med Sci. 2024. PMID: 39006841 Free PMC article.

• Aggregation-induced integrated stress response rejuvenates culture-expanded human mesenchymal stem cells.

  Bijonowski BM, Fu Q, Yuan X, Irianto J, Li Y, Grant SC, Ma T. Bijonowski BM, et al. Biotechnol Bioeng. 2020 Oct;117(10):3136-3149. doi: 10.1002/bit.27474. Epub 2020 Jul 5. Biotechnol Bioeng. 2020. PMID: 32579299 Free PMC article.

• Effects of Oxidative Stress on Mesenchymal Stem Cell Biology.

  Denu RA, Hematti P. Denu RA, et al. Oxid Med Cell Longev. 2016;2016:2989076. doi: 10.1155/2016/2989076. Epub 2016 Jun 16. Oxid Med Cell Longev. 2016. PMID: 27413419 Free PMC article. Review.

• [Efficacy and security of matched unrelated donor hematopoietic stem cell transplant with transfusion of multipotent mesenchymal cells in pediatric severe aplastic anemia].

  Wang L, Wang HX, Zhu L, Zheng XL, Wang ZD, Yan HM, Ding L, Han DM. Wang L, et al. Zhonghua Xue Ye Xue Za Zhi. 2016 Jun 14;37(6):453-7. doi: 10.3760/cma.j.issn.0253-2727.2016.06.002. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27431066 Free PMC article. Chinese.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program